STOCK TITAN
  1. Home
  2. News
  3. IPHA

Innate Pharma S.A. ADS - $IPHA STOCK NEWS

Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: $IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innate Pharma S.A. ADS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innate Pharma S.A. ADS's position in the market.

News
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
Rhea-AI Summary

Innate Pharma SA has scheduled a conference call and webcast on May 14, 2024, to discuss the business progress during the first quarter of 2024. Key executives will provide updates on the company's performance and future plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
earnings
-
News
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Rhea-AI Summary
Innate Pharma will hold its Annual General Meeting of Shareholders on May 23, 2024, at its headquarters in Marseille, France. The meeting will include the agenda, proposed resolutions, and instructions for participation and voting. Shareholders must register their shares in advance to participate, with additional details available on the company's website. A guided tour of the company's laboratories will also be offered to shareholders on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
News
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
Rhea-AI Summary
Innate Pharma announced the advancement of Sanofi-developed NK cell engager SAR443579 / IPH6101 to Phase 2 for blood cancer patients. The first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial, triggering a €4m milestone payment to Innate. SAR443579 is being evaluated as a monotherapy for blood cancers with high unmet needs, including R/R AML, B-cell acute lymphoblastic leukemia, and high-risk myelodysplasia. The drug received FDA Fast Track Designation for the treatment of acute myeloid leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
clinical trial
News
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Rhea-AI Summary
Innate Pharma SA announces promising preclinical data for IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, showing stronger activity than EV in urothelial tumors. IPH45 demonstrates anti-tumor efficacy in various solid tumors and EV-refractory models, with plans for IND in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
News
Innate Pharma Announces Its Participation in Upcoming Investor Conference
Rhea-AI Summary
Innate Pharma SA (Nasdaq: IPHA) executives to attend Van Lanschot Kempen conference in Amsterdam on April 16-17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
Rhea-AI Summary
Innate Pharma (IPHA) files 2023 Universal Registration Document and annual report on Form 20-F with AMF and SEC, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
News
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
Rhea-AI Summary
Innate Pharma reports positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome, licensing of a fourth NK cell engager ANKET® by Sanofi, and other significant milestones achieved in 2023. The company's cash position stands at €102.3 million as of December 31, 2023, with a cash runway to the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
earnings
-
News
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Rhea-AI Summary
Innate Pharma SA executives to participate in the 2nd Annual H.C. Wainwright Cell Therapy Virtual Conference on March 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
-
News
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) announced a conference call on March 21, 2024, to discuss financial results for the full year ending December 31, 2023. Key participants include the CEO, CMO, COO, CFO, and President of US Operations. The event will be live webcasted and accessible via telephone. A replay will be available on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
earnings
News
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
Rhea-AI Summary
Innate Pharma announces that its preclinical asset IPH45, a topoisomerase I inhibitor ADC targeting Nectin-4, has been selected for oral presentation at the AACR Annual Meeting 2024. The abstract highlights promising preclinical data showing effective tumor growth inhibition and a favorable safety profile, advancing IPH45 towards clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences clinical trial
Stock IPHA logo
Innate Pharma S.A. ADS

Nasdaq:IPHA

IPHA Rankings

#3767 Ranked by Market Cap
#1070 Ranked by Stock Gains
N/A Ranked by Dividends

IPHA Stock Data

207.76M
30.66M
0.11%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Marseille

About IPHA

innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma